Celgene Phase I/II Revimid myeloma data

CELG reported data from 2 U.S. Phase I/II trials of Revimid in refractory multiple myeloma. In the first trial, 19 of 24 evaluable patients achieved stable disease and 63% of patients had >25% reducti...